PolyPeptide Confirms Strategic Review Amid Takeover Speculation

PolyPeptide Group AG ( (CH:PPGN) ) just unveiled an update.

PolyPeptide Group AG, a global CDMO for peptide-based active pharmaceutical ingredients, supports customers from pre-clinical to commercial stages across a broad portfolio, particularly in metabolic diseases. The Swiss-listed company operates a network of six GMP-certified sites and targets fast-growing therapeutic markets worldwide.

The company acknowledged recent market rumors of takeover interest but reiterated its policy of not commenting on speculation. Its board, working with majority shareholder Draupnir Holding, has begun an early-stage review of strategic options while emphasizing continued execution of its strategic plan, including an ambition to double 2023 revenue by 2028.

PolyPeptide stressed that no decisions have been made and there is no assurance the strategic review will lead to a transaction or other outcome. Management underscored that the company remains focused on long-term value creation for shareholders, customers and other stakeholders, supported by strong growth potential reflected in its 2026 guidance.

The most recent analyst rating on (CH:PPGN) stock is a Buy with a CHF44.00 price target. To see the full list of analyst forecasts on PolyPeptide Group AG stock, see the CH:PPGN Stock Forecast page.

More about PolyPeptide Group AG

PolyPeptide Group AG is a specialized contract development and manufacturing organization focused on peptide-based active pharmaceutical ingredients for pharma and biotech customers. Operating six GMP-certified facilities across Europe, the U.S. and India, it serves a fast-growing market, with a strong presence in metabolic disease therapies including GLP-1 drugs.

Average Trading Volume: 72,085

Technical Sentiment Signal: Buy

Current Market Cap: CHF1.05B

For a thorough assessment of PPGN stock, go to TipRanks’ Stock Analysis page.